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     Tumor necrosis factor- α (TNF-α) plays an important role in diverse cellular events such as septic shock, 
induction of other cytokines, cell proliferation and apoptosis. Tumor necrosis factor (TNF)-related 
apoptosis-inducing ligand (TRAIL) is currently attracting great interest as a potential anticancer drug. 
TRAIL could selectively induce apoptosis in tumor cells in vitro and in vivo by a death receptor-mediated 
process. TRAIL shows a high degree of promiscuity as it binds to the DR5 receptor and it  is generating 
considerable interests as a possible anticancer therapeutic agent. Use of TRAIL or its antagonist could be a 
good anticancer treatment in future. The extracellular domain of DR5 human protein which has the 
attachment part of this ligand to TRAIL ligand is considerable domain of it. We produced a small peptide 
with just 15 aminoacids from this domain, with peptide synthesizer. Then inject them to hens to immunize 
them and achieve high affinity IgY. At least, obtained IgYs specially recognize DR5 protein and in vitro 
start exclusively to induce death in the MCF7 cell line, and interestingly not on normal cells. 
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INTRODUCTION   
     Nowadays cancer is the second cause of death 
among human. If a branch of cells could not 
remove the cells with genetical damages, beyond 
more and more amplification of them, they go out 
of control and cancerous cells birth. In the other 
words, the cells forget the dying. Cancer is 
subsequent of series of mutations in growth, cell 
cycle control, apoptosis inducing and oncogene 
genes. Furthermore these mutations disrupt the 
natural process of the cells [1,2]. Ligation of death 
receptors of the tumor necrosis factor receptor 
super family such as CD95 (APO-1/Fas) or tumor 
necrosis factor-related apoptosis-inducing ligand 
(TRAIL) receptors by their corresponding natural 
ligands results in the recruitment of caspase-8 into 
multimeric complex at the plasma membrane, the 
death inducing signaling complex (DISC) [3]. 
Among these receptors, it seems TRAIL receptors 
have more specificity for cancerous cells [4-7]). 
 TRAIL shows a high degree of promising as it 
binds to five cognate receptors: DR4 (TRAIL-R1) 
and DR5 (TRAIL-R2) and the decoy receptors 
DcR1 (TRAIL-R3), DcR2 (TRAIL-R4), and 
osteoprotegerin (OPG) [8]. DR4 or DR5 receptor-
specific TRAIL variants would permit new and 
tumor selective therapies. DR5 was described as 
contributing more than DR4 to the overall 
apoptotic activity of TRAIL in apoptosis signaling 
of cancer cells [9-11].  
Production of agonists of TRAIL like antibodies 
can lead to activation of these receptors. From two 
kinds of poly- and monoclonal antibodies,  the 
major problem of monoclonal antibody is that 
some antigens are weakly or not at all 
immunogenic for animals [12-15].  




During the past 20 years, the use of chickens against 
of mammals for antibody production has  increased. 
A major advantage of using birds is that the 
antibodies can be harvested from the egg yolk 
instead of serum, thus they did not hurt animals. 
Additionally, antibody productivity of an egg-laying 
hens is much greater than that of a similar sized 
mammal [16]. The development of lipid based drug 
carrier has attracted increased attention over the last 
years. This lipid carriers are rapidly developing field 
of nanotechnology with several potential application 
in drug delivery clinical medicine and research, 
adjuvant [17]. Protection of incorporated active 
compounds against chemichal and enzymatical 
degradation and more flexibly in modulating the 
release of the compound, they are composed [18]. 
The combination of such advantages, occupying the 
death receptor with an antibody that produced in 
birds, can give a strong weapon against MCF7 
cancerous cells. In this study we choose a small part 
of the extracellular domain of the DR5-receptor, 
synthesized it and used for immunization of the 
hens. At least evaluate its effect on breast cancer 
Cells. 
 
MATERIALS AND METHODS 
Peptide production:  
    A 15 amino acids peptide is produced in peptide 
synthesis center of National Institute of Genetic 
Engineering & Biotechnology.  
Liposome prepration:  
    Liposome were prepared by the 
dehydration/rehydreation process. Lipids (lesitin, 
500 mg, cholesterol 5 mg) was dissolved in ethanol 
(25 ml) and dried to film in a round-bottom flask 
using a rotator evaporator at 50
0
C. The film was 
solved in sterile PBS (20 ml, Na2HPO4 5.8 gr, 
KH2PO4 1.63gr, NaCl                5.3 gr ). The mixture 
was sonicated (600 herts, 5 minutes) and then added 
dextran (2.5 mg). Then the performed liposome 
were dehydrated by freeze-drying using a 
liophilizer. They were sealed and stored in a 
refrigerator at -20C. 
Immunization of hens 
     Immunization of hens was performed in animal 
house of Pastour institute (Tehran, Iran) with a total 
350µg of peptide which was encapsulated in 
liposomal structure. 
ELISA  
    Ninety-six-well ELISA plates were coated O/N 
with 20µg of either recombinant synthesized 
peptide and incubate coating buffer for one over-
night in 4
o
C. The coating was followed by 60 min 
incubation with blocking buffer then incubate for 
45 min with the tested IgY antibody (dilutions 
1:100 to 1:1600 were used), then  30 min 
incubation with secondary antibodies (goat 
derived anti-hen-IgG) ,HRP conjugated. We have 
washing in every step for 3 times with PBST.  In 
the detection step, add 100µl TMB solution and 
absorbance was measured at either 490 nm  
(reactions stopped with 1 N hydrochloric acid). 
Isolation and purification of IgY:  
    Isolation of IgY was carried out by separation 
of the egg yolk from the white part. The egg yolk 
was added two volumes of phosphate buffer 
(sodium phosphate 0.1M, NaCl 10mM, pH=7). 
The solution was then mixed with magnetic 
stirrer. Then add two volume chloroform and 
incubate in 4
0
C for 20 minutes. Centrifuge the 
solution in 14000 ×g, for 20 minute, collect the 
supernatant and discard the plate. 12% (w/v) poly 
ethylene glycol (PEG6000) was added to the 
supernatant and mixed with magnetic stirrer for 
20 minutes to remove lipoproteins. The mixture 
was centrifuged at 14000 ×g, 10 minute at 4
o
C 
and the supernatant was discard and sediment 
resolved in PBS (PH=7.4). For more purification 
of IgY repeat the last step three. At least the 
sediment was then resuspended in equal volume 




MTT assay:  
    The MTT method of cell determination is done 
in three days on MCF7 cell line (human breast 
cancer). First cultured 10000cells per well in the 
first day and incubate it for 24 hours. In the 
second day, remove media carefully and treat 
cells with against, antibodies (final volume should 
be 100 μl). Day three remove the supernatant and 
add 100 μl of 5 mg/ml MTT to each well. 
Incubate them for 2 hours at 37
0
C, 5% CO2 in 
culture incubator. Carefully remove media and  
resolve the color in MTT solvent (isopropanol). 
Read the absorbance at 590 nm. Then calculate 
the data with Farms software.  






     Produced liposomal compositions were in a 
nano scale. However, liposomal size was meseared 
with Zetasizer nano. The ranges of liposomal 
suspension for liposome without cargo were 11.7 
nm and for liposoms with peptides were 73.5 nm 
(figure 1). The obtained milky liquid of liposomal 
constructions encapsulated 1 mg/ml of 15 
aminoacids peptide. Indeed, the differences 
between free and loaded liposome configure the 
encapsulation.   
IgY production 
    ELISA assay was performed to stimulate 
antibody production and its specificity. 
Furthermore, after adding the purified IgYs to the 
coated wells, they attach remarkably to the 
peptides (figure 2). According to the small size of 
the injected peptides the amount of the antibody 
titer was significant. 
    MTT results 
To estimating the ability of IgY-15L to kill the 
MCF7 cancerous cells, MTT assay was used. The 
result showed that IgY-15L with 2.5 µg/ml kill the 
50% of MCF7 cells selectively. According to the 
specific interaction of IgY-15Lwith DR5 receptor, 
that seems it can induces the death cascade in these 
cells (figure 3). 
 
  
Figure 1. A histogram of liposom size distribution 
determined by DLS. The diameter shown is the 
hydrodynamic diameter of the free liposome (A) and 
liposomes that were loaded with peptides (B).  
 
Figure 2. ELISA assay result of IgY that produced against 
15 aminoacids of extracellular part of DR5 protein.15L is 
antibody that produced against nanoliposomal 15 amino 
acids peptide, control L is antibody against just free 




Figure 3. MTT assay results. The result toxicity per cent of 
IgGs (15L and control L) on MCF7 cell line. The means 
differences for P<0.05 has sense. The percentage of toxicity 
was calculated using the following formula: %toxicity= 
(AT/AUT – 1)×100, where AT is absorbance of treated cells, 
and AUT is absobance of untreated cells. 
 
DISCUSSION 
     In recent years, a surge in our knowledge about 
programmed cell death (apoptosis) has established 
its role in the regulation of tumorigenesis. 
Apoptosis is an active, energy-dependent process 
that mediates the elimination of cells that have 
developed improperly, or sustained irreparable 
genetic damage [19]. At the end point we started 




apoptosis process in an another properly substitute 
pathway upon dead receptors. It seems death 
receptors are a good one. TRAIL is a 32 kDa 
transmembrane protein expressed in a wide range 
of normal fetal and adult tissues, suggesting the 
existence of a protective mechanism against its 
cytotoxicity in normal cells. This is supported by 
observations that TRAIL can induce apoptosis in 
transformed and malignant cells, but not in 
normal cells. TRAIL induces apoptosis by 
interacting with two cell-surface receptors, DR4 
and DR5 [20]. The selective nature of the 
anticancer activity of TRAIL was demonstrated 
by studies in mice and non-human primates 
[21,22].  
After Klemperer discovery that the immunization 
of hens results in transfering the specific IgY from 
serum to eggs till now, the Scientifics produce 
several kinds of IgYs that can stop or control their 
target pathological organisms [23,24]. The use of  
chicken IgY, instead of IgG mammalian 
antibodies, to detect non-self or even self 
antigens, certainly may help lower costs of 
clinical or research immunological tests. In 
addition, chicken antibodies do not activate the 
mammalian complement system nor interact with 
rheumatoid factors, or bacterial and human Fc 
receptors. It seems using the antibody produced 
by hens to attaching this receptor and mimicking 
its work can be efficient. As we see, the antibody 
against a small part of the extracellular domain of 




    The present study introduce a functional and 
efficient new agent in cancer therapy. Such 
specific antibody could find cancer cells and kill 
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